ALEC - Company ID 0001653087
Alector, Inc. trades as ALEC. In its fiscal 2025 annual report the company posted revenue of $21.05M, down 79.1% from the prior year and net income of -$143.00M. This page tracks Alector, Inc. through 580 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 8 fiscal years Alector, Inc.'s revenue grew from $3.73M to $21.05M, a compound annual growth rate of 24.1%. Net profit margin expanded from -869.6% to -679.5% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-14 |
| Major company event | 8-K | 2026-05-07 |
| Prospectus supplement | 424B5 | 2026-05-07 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| EFFECT | - | 2026-04-30 |
| Annual report to shareholders | ARS | 2026-04-28 |
| Proxy materials | DEFA14A | 2026-04-28 |
The largest companies sharing Alector, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Alector, Inc. reported revenue of $21.05M for fiscal year 2025, a decrease of 79.1% year over year.
In its latest fiscal year Alector, Inc. reported a net loss of $143.00M.